Vendor, Bradenton, FL
Continuity Biosciences, LLC
UEI KTR8EE8DBFX5, CAGE 13F55
1 award and $2,995,581 obligated between August 22, 2025 and August 18, 2026, 100% under full and open competition, against 16.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $2,995,581 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 1 |
| Small Business Set Aside - Total | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N91025C00024Definitive Contract, August 22, 2025, Full and Open Competition After Exclusion of Sources, 16 offers | NIH NCINational Institutes of Health | Direct to Phase II SBIR Concept Award for Novel Iontophoretic Drug Delivery Device for Local and Effective Treatment of Oral CancerNAICS 541715, PSC AN12 | $2,995,581 |
- Places of performance
- North Carolina
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 3 across 1 awards